This in vitro observation could be recaptured in p53 mutated breast cancer patients, as the expression of CPT1C is lower in the cohort of miR-200c-High when compared with patients harboring low miR-200c expression (Figure 6E). This evidence concerns the gene TP53 and breast cancer.